CJC-1295 without DAC is a research peptide commonly identified as Modified GRF (1-29). It is studied in relation to growth hormone-releasing hormone (GHRH) receptor signalling and growth hormone secretion. It does not contain the drug affinity complex (DAC) used in the long-acting form of CJC-1295.
This product is supplied for controlled laboratory research. Refer to the individual listing and batch documentation for the vial strength and product specifications.
Product Details
| Component | Details |
|---|---|
| Compound | CJC-1295 without DAC |
| Common research name | Modified GRF (1-29) |
| Research category | GHRH receptor and growth hormone signalling |
| Vial strength | As stated on the selected product listing |
What Is CJC-1295 Without DAC Studied For?
Preclinical and laboratory research only
GHRH receptor activity: Research examines how GHRH-related peptides interact with receptors involved in growth hormone signalling.
Growth hormone secretion: Studies of GHRH (1-29) have investigated growth hormone responses following receptor stimulation.
Growth hormone signalling patterns: Researchers may examine the timing and regulation of growth hormone release in experimental models. Published findings for CJC-1295 with DAC describe a different, longer-acting compound and should not be applied directly to the version without DAC.
Research Use Notice
FOR RESEARCH PURPOSES ONLY. This Riptide product is intended for laboratory research and is not offered for human or veterinary use. It is not intended for therapeutic or diagnostic purposes. Handle and store according to applicable laboratory procedures and the product’s batch documentation.
